Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
Published on June 28, 2024
June 28, 2024 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, consistent with the recommendations of the management.
The detailed results of the vote and the resolutions are available on Cellectis’ website:
https://www.cellectis.com/en/investors/general-meetings/